How should the medication regimen (buspirone 15 mg three times daily, fluoxetine 20 mg each morning, bupropion extended‑release 450 mg each morning with food, hydroxyzine 10 mg three times daily as needed, and lurasidone 40 mg each evening with at least 350 kcal) be adjusted for an adult male with social anxiety disorder, schizoid personality disorder, and chronic insomnia (taking up to two hours to fall asleep)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medication Regimen Optimization for Social Anxiety, Schizoid Personality Disorder, and Insomnia

The current regimen requires significant modification: discontinue buspirone (ineffective for social anxiety), reduce bupropion XL to 300 mg or consider switching to an SSRI, and add a targeted sleep intervention such as low-dose trazodone or doxepin for the chronic insomnia.

Primary Issues with Current Regimen

Buspirone for Social Anxiety: Not Evidence-Based

  • Buspirone should be discontinued. The highest-quality evidence shows buspirone is ineffective for social anxiety disorder. A double-blind placebo-controlled trial found no statistically significant differences between buspirone 30 mg daily and placebo on any outcome measures for social phobia, with only 1 patient (out of 30) responding to buspirone versus 1 on placebo 1.
  • While buspirone has FDA approval for generalized anxiety disorder 2, the Japanese guideline for social anxiety disorder recommends SSRIs and SNRIs specifically, not buspirone 3.
  • The hydroxyzine PRN is more appropriate for acute anxiety management than buspirone for this indication 4.

Bupropion XL 450 mg: Dose Concerns

  • The 450 mg dose is the maximum FDA-approved dose and may be exacerbating anxiety and insomnia. Recent evidence suggests bupropion can have mixed effects on anxiety—while it may reduce anxiety symptoms in some depressed patients, its stimulating properties can provoke anxiety, particularly at higher doses 5.
  • Bupropion is associated with increased insomnia as a common side effect 6, which directly conflicts with this patient's sleep difficulties.
  • Reduce to 300 mg daily or consider switching to an SSRI (fluoxetine can be increased, or switch to sertraline/escitalopram), which are first-line for social anxiety 3.

Fluoxetine 20 mg: Underdosed for Social Anxiety

  • If continuing with an SSRI approach, fluoxetine 20 mg is likely subtherapeutic for social anxiety disorder. Typical effective doses for anxiety disorders range from 40-60 mg daily.
  • SSRIs are the guideline-recommended first-line pharmacotherapy for social anxiety disorder 3.

Lurasidone 40 mg: Appropriate but Monitor

  • Lurasidone is being taken correctly with adequate calories (≥350 kcal required for absorption) 7.
  • This is appropriate for the schizoid personality disorder features, particularly if there are any attenuated psychotic symptoms or mood instability.
  • Continue current dose unless side effects emerge.

Insomnia: Unaddressed

  • The 2-hour sleep latency represents significant chronic insomnia that is not being adequately treated. The American College of Physicians guideline emphasizes that insomnia disorder causes daytime distress and dysfunction 8.
  • Bupropion at 450 mg is likely worsening this problem.
  • Lurasidone taken at dinner may provide some sedation, but clearly insufficient.

Recommended Medication Algorithm

Step 1: Address Social Anxiety with Evidence-Based Treatment

Option A (Preferred):

  • Discontinue buspirone (ineffective for social anxiety)
  • Increase fluoxetine to 40 mg daily, with potential titration to 60 mg if needed after 4-6 weeks
  • Reduce bupropion XL to 300 mg daily (or discontinue if depression is adequately controlled by fluoxetine alone)

Option B (If activating effects are problematic):

  • Switch from fluoxetine to sertraline 100-200 mg daily or escitalopram 10-20 mg daily (both have strong evidence for social anxiety) 3
  • Discontinue buspirone
  • Discontinue or reduce bupropion XL

Step 2: Treat Chronic Insomnia

  • Add a sedating agent specifically for sleep:

    • Trazodone 50-100 mg at bedtime (off-label but widely used, minimal abuse potential)
    • Doxepin 3-6 mg at bedtime (FDA-approved for insomnia, particularly sleep maintenance)
    • Avoid benzodiazepines given the long-term risks of dependence, cognitive impairment, and falls 8

  • The insomnia guideline notes that most hypnotics have significant risks including dementia, fractures, and next-morning impairment 8, making low-dose sedating antidepressants a safer chronic option.

Step 3: Continue Supportive Medications

  • Continue lurasidone 40 mg at dinner with ≥350 calories 7
  • Continue hydroxyzine 10 mg TID PRN for breakthrough anxiety (more evidence-based than buspirone for acute anxiety) 4

Specific Dosing Recommendations

Immediate changes:

  1. Discontinue: Buspirone 15 mg TID
  2. Reduce: Bupropion XL from 450 mg to 300 mg daily (take in morning with food)
  3. Increase: Fluoxetine from 20 mg to 40 mg each morning
  4. Add: Trazodone 50 mg at bedtime (can increase to 100 mg after 3-5 days if tolerated and needed)
  5. Continue: Lurasidone 40 mg at dinner with ≥350 calories
  6. Continue: Hydroxyzine 10 mg TID PRN

Reassess in 4-6 weeks:

  • If social anxiety persists: increase fluoxetine to 60 mg daily
  • If insomnia persists: increase trazodone to 100-150 mg at bedtime
  • If depression worsens with bupropion reduction: consider returning to 450 mg or adding back, but only if sleep improves with trazodone

Critical Considerations

Drug Interactions

  • Fluoxetine is a strong CYP2D6 inhibitor, which has minimal interaction with this regimen but should be noted for future medication additions 2.
  • Bupropion is a CYP2D6 inhibitor, which is why it's combined with dextromethorphan in Auvelity 6, but this is not relevant to the current regimen.

Schizoid Personality Disorder

  • This personality disorder is characterized by social detachment and restricted emotional expression, which differs from social anxiety disorder (fear of negative evaluation).
  • The lurasidone addresses any attenuated psychotic features or cognitive-perceptual distortions that may accompany schizoid traits.
  • SSRIs may help with any comorbid anxiety but are less likely to modify core personality features.

Monitoring Parameters

  • Sleep latency and total sleep time (patient self-report or sleep diary)
  • Social anxiety symptoms using standardized measures if possible
  • Activation/agitation when adjusting bupropion or SSRIs
  • Metabolic parameters with lurasidone (weight, glucose, lipids) 7
  • Sexual function (SSRIs commonly cause dysfunction; bupropion does not) 6

Common Pitfalls to Avoid

  1. Do not continue buspirone for social anxiety—it lacks efficacy despite being used historically 1.
  2. Do not ignore the insomnia—chronic sleep deprivation worsens all psychiatric conditions and quality of life 8.
  3. Do not use maximum-dose bupropion (450 mg) as first-line in anxious patients—it can worsen anxiety and insomnia 5.
  4. Do not forget the 350-calorie requirement with lurasidone—absorption is substantially reduced without food 7.

Cognitive Behavioral Therapy

  • The Japanese guideline strongly recommends CBT specifically designed for social anxiety disorder (Clark and Wells or Heimberg models) 3.
  • This patient should be referred for individual CBT if available, as it addresses the core cognitive distortions in social anxiety.
  • CBT for insomnia (CBT-I) is also first-line for chronic insomnia but may be less accessible 8.

References

5
Research

Bupropion and Anxiety: A Brief Review.

Human psychopharmacology, 2025

6
Research

The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacology bulletin, 2024

Related Questions

What recommendations should be considered for an adult patient experiencing increased anxiety while taking bupropion (Wellbutrin) 300 mg daily, buspirone (Buspar) 10 mg three times daily, and cariprazine (Vraylar) 3 mg daily?
What medication adjustments do you recommend for a patient taking citalopram 10 mg daily and bupropion (Wellbutrin) 150 mg twice daily who continues to have occasional anxiety?
In a 59-year-old female nursing-home resident with depression, anxiety, and a history of alcohol abuse who is taking bupropion XL (bupropion) 300 mg daily, escitalopram 20 mg daily, trazodone 100 mg at bedtime and 25 mg in the morning, amphetamine/dextroamphetamine (Adderall) 10 mg daily, and divalproex sodium (Depakote) 250 mg twice daily, and who now presents with worsening depression, social isolation, increased daytime sleepiness, and anhedonia, what is the optimal psychotropic treatment approach?
What is the appropriate initiation, titration, and monitoring plan for bupropion maintenance therapy in a 27-year-old woman with mixed anxiety and depressive disorder?
In a 23-year-old male with anxiety and depression who smokes and wishes to quit, is bupropion (Wellbutrin) an appropriate treatment choice?
What is the appropriate doxycycline dose for an adult non‑pregnant patient with an uncomplicated mild urinary tract infection and no known allergies or severe renal impairment?
What dye‑free antibiotic regimen is recommended for treating streptococcal pharyngitis?
Should patients remain intubated after tracheal resection with primary anastomosis?
Does an elevated kappa/lambda free light chain ratio with elevated kappa free light chains, normal lambda, normal MCHC, and low absolute lymphocyte count indicate a monoclonal gammopathy that requires further evaluation?
In a 68-year-old woman with total cholesterol 198 mg/dL, triglycerides 65 mg/dL, HDL‑C 86 mg/dL, LDL‑C 102 mg/dL, and non‑HDL‑C 112 mg/dL, what is the recommended management?
In a female with irregular menstrual cycles, a normal pelvic ultrasound, and LH 3.9 IU/L and FSH 6.2 IU/L (LH/FSH ratio <2), what are the appropriate next diagnostic and management steps?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.